However, soticlestat, an inhibitor of cholesterol 24-hydroxylase that reduces inflammatory markers, failed to meet primary clinical endpoints for seizure reduction in Dravet syndrome and Lennox–Gastaut syndrome [102], despite favorable results in a mouse model of Dravet syndrome [103]. Here, CYP46A1 is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.